Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia

Adam Lamble, MD, Yoko Kosaka, PhD, Fei Huang, A Kate Sasser, PhD, Homer Adams, III, PhD, Cristina E. Tognon, Ted Laderas, PhD, Shannon K. McWeeney, Marc M. Loriaux, Jeffrey W. Tyner, Brian J. Druker, MD, Evan F. Lind, PhD

Blood (2016) 128 (22): 2829.

https://doi.org/10.1182/blood.V128.22.2829.2829

Published: 2016

Journal Articles

Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia

Jessica T Leonard, MD, Bill H. Chang, MD PhD, Jeffrey W. Tyner, PhD, Brandon Hayes-Lattin, MD, Marc M. Loriaux, Brian J. Druker, Uma Borate, MD

Blood (2016) 128 (22): 2811.

https://doi.org/10.1182/blood.V128.22.2811.2811

Published: 2016

Journal Articles

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood (2016) 128 (22): 1119.

https://doi.org/10.1182/blood.V128.22.1119.1119

Published: 2016

Journal Articles

Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia

Blood (2016) 128 (22): 4056.

https://doi.org/10.1182/blood.V128.22.4056.4056

Published: 2016

Journal Articles

Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway

Jessica T Leonard, MD, Jeffrey W. Tyner, PhD, Joelle Rowley, Marc M. Loriaux, Brian J. Druker, Bill H. Chang, MD PhD

Blood (2016) 128 (22): 1583.

https://doi.org/10.1182/blood.V128.22.1583.1583

Published: 2016

Journal Articles

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression

Philip A. Beer, David J. H. F. Knapp, Paul H. Miller, Nagarajan Kannan, Ivan Sloma, Kathy Heel, Sonja Babovic, Elizabeth Bulaeva, Gabrielle Rabu, Jefferson Terry, Brian J. Druker, Marc M. Loriaux, Keith R. Loeb, Jerald P. Radich, Wendy N. Erber, Connie J. Eaves

Blood (2015) 125 (3): 504–515.

https://doi.org/10.1182/blood-2014-06-581173

Published: 2015

Includes: Supplemental data

Journal Articles

The Bromodomain Inhibitor CPI203 Demonstrates Preclinical Synergistic Activity with Bortezomib in Drug Resistant Myeloma

Matthew B. Siegel, MD, Monika A. Davare, PhD, Selina Qiuying Liu, BS, Stephen E. Spurgeon, MD, Marc M. Loriaux, Brian J. Druker, Emma C. Scott, MD, Jeffrey W. Tyner

Blood (2014) 124 (21): 4702.

https://doi.org/10.1182/blood.V124.21.4702.4702

Published: 2014

Journal Articles

Activating Mutations Observed in De Novo Acute Myeloid Leukemia Are Also Present in a Subset of Philadelphia Chromosome (Ph)-Positive Leukemia Patients with BCR-ABL1-Independent Resistance to ABL1 Kinase Inhibitors

Christopher A. Eide, Samantha L. Savage, Anupriya Agarwal, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Stephen E. Kurtz, Thomas O'Hare, Michael W. Deininger, Marc M. Loriaux, Cristina E. Tognon, Jeffrey W. Tyner, Brian J. Druker

Blood (2014) 124 (21): 4514.

https://doi.org/10.1182/blood.V124.21.4514.4514

Published: 2014

Journal Articles

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein

Anupriya Agarwal, Ryan J. Mackenzie, Arnaud Besson, Sophia Jeng, Alyssa Carey, Dorian H. LaTocha, Angela G. Fleischman, Nicolas Duquesnes, Christopher A. Eide, Kavin B. Vasudevan, Marc M. Loriaux, Eduardo Firpo, Jorge E. Cortes, Shannon McWeeney, Thomas O’Hare, James M. Roberts, Brian J. Druker, Michael W. Deininger

Blood (2014) 124 (22): 3260–3273.

https://doi.org/10.1182/blood-2013-04-497040

Published: 2014

Includes: Supplemental data

Journal Articles

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

Angela G. Fleischman, Julia E. Maxson, Samuel B. Luty, Anupriya Agarwal, Lacey R. Royer, Melissa L. Abel, Jason D. MacManiman, Marc M. Loriaux, Brian J. Druker, Jeffrey W. Tyner

Blood (2013) 122 (22): 3628–3631.

https://doi.org/10.1182/blood-2013-06-509976

Published: 2013

Includes: Supplemental data

Journal Articles

Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors

Christopher A. Eide, Samantha L. Savage, Jade Bryant, Anupriya Agarwal, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Thomas O'Hare, Michael W. Deininger, Marc M. Loriaux, Cristina E. Tognon, Jeffrey W. Tyner, Brian J. Druker

Blood (2013) 122 (21): 3994.

https://doi.org/10.1182/blood.V122.21.3994.3994

Published: 2013

Journal Articles

The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization

Blood (2013) 122 (21): 270.

https://doi.org/10.1182/blood.V122.21.270.270

Published: 2013

Journal Articles

CSF3R T618I Mouse Bone Marrow Transplant Model Of Neutrophilic Leukemia

Julia E Maxson, PhD, Angela G. Fleischman, MD, PhD, Samuel B Luty, BS, Lacey R Royer, Anupriya Agarwal, Marc M. Loriaux, Brian J. Druker, Jeffrey W. Tyner

Blood (2013) 122 (21): 223.

https://doi.org/10.1182/blood.V122.21.223.223

Published: 2013

Journal Articles

A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.

Julia E Maxson, PhD, Jason Gotlib, Angela G. Fleischman, MD, PhD, Christopher A. Eide, Daniel Bottomly, MS, Beth Wilmot, PhD, MS, Shannon McWeeney, PhD, Cristina Tognon, PhD, Marc M Loriaux, MD, PhD, Brian J. Druker, Jeffrey W Tyner, PhD

Blood (2012) 120 (21): 2412.

https://doi.org/10.1182/blood.V120.21.2412.2412

Published: 2012

Journal Articles

CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-Δ Inhibitor GS-1101 or Fludarabine.

Renee C Prins, M.D., Russell T Burke, Marc M Loriaux, MD, PhD, Brian J. Druker, Stephen E Spurgeon, MD

Blood (2012) 120 (21): 2471.

https://doi.org/10.1182/blood.V120.21.2471.2471

Published: 2012

Journal Articles

Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.

Marie O'Farrell, PhD, Richard Ventura, Albert Tai, Jeffrey W Tyner, PhD, Marc M Loriaux, MD, PhD, Daruka Mahadevan, MD, PhD, Carla Morales, S. David Brown, David J Matthews, PhD

Blood (2012) 120 (21): 2907.

https://doi.org/10.1182/blood.V120.21.2907.2907

Published: 2012

Journal Articles

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

Russell T Burke, Astrid Clarke, Sarah A Meadows, Marc M Loriaux, MD, PhD, Jennifer B Dunlap, MD, Guang Fan, MD, PhD, Patricia Maciejewski, Julie Di Paolo, Brian J. Lannutti, PhD, Brian J. Druker, Stephen E Spurgeon, MD

Blood (2012) 120 (21): 3876.

https://doi.org/10.1182/blood.V120.21.3876.3876

Published: 2012

Journal Articles

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

Angela G. Fleischman, Karl J. Aichberger, Samuel B. Luty, Thomas G. Bumm, Curtis L. Petersen, Shirin Doratotaj, Kavin B. Vasudevan, Dorian H. LaTocha, Fei Yang, Richard D. Press, Marc M. Loriaux, Heike L. Pahl, Richard T. Silver, Anupriya Agarwal, Thomas O'Hare, Brian J. Druker, Grover C. Bagby, Michael W. Deininger

Blood (2011) 118 (24): 6392–6398.

https://doi.org/10.1182/blood-2011-04-348144

Published: 2011

Includes: Supplemental data

Journal Articles

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

Qian Yu, BS, Anna M Eiring, PhD, Matthew S. Zabriskie, Jamshid Khorashad, MD, PhD, David J Anderson, BS, Jade A Bryant, BS, Marc M Loriaux, MD, PhD, Jeffrey W Tyner, PhD, Thomas O'Hare, Michael W. Deininger

Blood (2011) 118 (21): 2481.

https://doi.org/10.1182/blood.V118.21.2481.2481

Published: 2011

Journal Articles

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

Renee C Prins, M.D., Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Luke B Fletcher, Abdusebur Jemal, Jade A Bryant, BS, Russell T Burke, Bill H Chang, MD, PhD, Tibor Kovacsovics, MD, Brian J. Druker, Marc M Loriaux, MD, PhD

Blood (2011) 118 (21): 3512.

https://doi.org/10.1182/blood.V118.21.3512.3512

Published: 2011

NARROW

Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia

Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia

Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression

The Bromodomain Inhibitor CPI203 Demonstrates Preclinical Synergistic Activity with Bortezomib in Drug Resistant Myeloma

Activating Mutations Observed in De Novo Acute Myeloid Leukemia Are Also Present in a Subset of Philadelphia Chromosome (Ph)-Positive Leukemia Patients with BCR-ABL1-Independent Resistance to ABL1 Kinase Inhibitors

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors

The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization

CSF3R T618I Mouse Bone Marrow Transplant Model Of Neutrophilic Leukemia

A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.

CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-Δ Inhibitor GS-1101 or Fludarabine.

Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only